Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/10010

Title: Use of Meta-Analysis for the Validation of Surrogate Endpoints and Biomarkers in Cancer Trials
Authors: BUYSE, Marc
Issue Date: 2009
Citation: CANCER JOURNAL, 15(5). p. 421-425
Abstract: This article discusses statistical approaches to the validation of surrogate biomarkers and endpoints. One approach that has been successfully used in oncology consists of estimating associations at two levels: the association between the surrogate and the clinical endpoint, called the individual-level association, and the association between the effects of treatment on the surrogate and the clinical endpoint, called the trial-level association. This approach requires data to be available from multiple randomized trials, such as in a meta-analysis of trials based on individual patient data. The approach is illustrated using randomized trials of first-line treatments for advanced tumors of the colon, breast, ovary, and prostate. Data from several meta-analyses suggest that progression-free survival is an acceptable surrogate in advanced colorectal and ovarian cancer, but not in breast and prostate cancer.
Notes: [Buyse, Marc] IDDI, B-1340 Louvain, Belgium. [Buyse, Marc] Hasselt Univ, Ctr Stat, I BioStat, Diepenbeek, Belgium.
URI: http://hdl.handle.net/1942/10010
ISI #: 000270918300012
ISSN: 1528-9117
Category: A1
Type: Journal Contribution
Validation: ecoom, 2010
Appears in Collections: Research publications

Files in This Item:

There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.